{
    "clinical_study": {
        "@rank": "13312", 
        "arm_group": [
            {
                "arm_group_label": "ACP-001, dose-level 1", 
                "arm_group_type": "Experimental", 
                "description": "Once weekly subcutaneous injection of ACP-001"
            }, 
            {
                "arm_group_label": "ACP-001, dose-level 2", 
                "arm_group_type": "Experimental", 
                "description": "Once weekly subcutaneous injection of ACP-001"
            }, 
            {
                "arm_group_label": "ACP-001, dose-level 3", 
                "arm_group_type": "Experimental", 
                "description": "Once weekly subcutaneous injection of ACP-001"
            }, 
            {
                "arm_group_label": "Human Growth Hormone", 
                "arm_group_type": "Active Comparator", 
                "description": "Once daily subcutaneous injection of human Growth Hormone (rhGH)"
            }
        ], 
        "brief_summary": {
            "textblock": "A six month study of ACP-001, a long-acting growth hormone product, versus standard human\n      growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone\n      (hGH) will be given on a daily basis. The primary aim is to demonstrate safety,\n      pharmacokinetics and pharmacodynamics over a period of six months. A secondary objective is\n      the comparison of height velocity (HV) of the ACP-001 treated groups to the daily hGH\n      treatment group."
        }, 
        "brief_title": "Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)", 
        "condition": "Growth Hormone Deficiency (GHD)", 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Prepubertal children, Tanner stage 1\n\n          -  Diagnosis of GHD, confirmed by two stimulation tests\n\n          -  Bon age not greater than chronological age\n\n          -  Impaired height and height velocity\n\n          -  BMI within +/- 2 SD\n\n          -  Baseline IGF-I\n\n          -  Normal fundoscopy\n\n          -  Stable hormonal replacement therapy (other than hGH)\n\n          -  Written Informed Consent\n\n        Exclusion Criteria:\n\n          -  Prior exposure to rhGH or IGF-I\n\n          -  Past or present intracranial tumor; history or presence of malignant disease\n\n          -  Small for gestational age (SGA)\n\n          -  Malnutrition\n\n          -  Psychosocial dwarfism\n\n          -  Coeliac disease\n\n          -  Anti-hGH antibodies\n\n          -  Diabetes mellitus\n\n          -  Chromosomal abnormalities (e.g. Turner syndrome, SHOX)\n\n          -  Closed epiphyses\n\n          -  Known or suspected HIV infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947907", 
            "org_study_id": "ACP-001_CT-004"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ACP-001, dose-level 1", 
                    "ACP-001, dose-level 2", 
                    "ACP-001, dose-level 3"
                ], 
                "description": "Once weekly subcutaneous injection", 
                "intervention_name": "ACP-001", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Human Growth Hormone", 
                "description": "Once daily subcutaneous injection of human Growth Hormone", 
                "intervention_name": "Human Growth Hormone", 
                "intervention_type": "Drug", 
                "other_name": "Somatropin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Human Growth Hormone", 
            "rhGH", 
            "hGH", 
            "GHD"
        ], 
        "lastchanged_date": "September 18, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany"
                    }, 
                    "name": "University of Leipzig"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany"
                    }, 
                    "name": "University of Magdeburg"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "University of Budapest"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pecs", 
                        "country": "Hungary"
                    }, 
                    "name": "University of Pecs"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary"
                    }, 
                    "name": "University of Szeged"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Samara", 
                        "country": "Russian Federation"
                    }, 
                    "name": "University of Samara"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ufa", 
                        "country": "Russian Federation"
                    }, 
                    "name": "University of Ufa"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Hungary", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Phase 2, Randomized, Open Label, Active-controlled, Parallel-group Study Investigating the Safety, Tolerability, and Efficacy of Different Dose Levels of ACP-001 Administered Once Weekly Versus Standard Daily rhGH Replacement Therapy in Pre-pubertal Children With Growth Hormone Deficiency (GHD)", 
        "overall_contact": {
            "email": "mb@ascendispharma.com", 
            "last_name": "Michael Beckert, MD", 
            "phone": "+4536944486"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Lyon", 
                "last_name": "Pierre Chatelain, Prof, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ascendis Pharma A/S", 
                "last_name": "Michael Beckert, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: Ministry of Health, Social and Family Affairs", 
                "Czech Republic: State Institute for Drug Control"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of adverse events", 
                "measure": "Safety of ACP-001 on different dosing levels", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Pharmacokinetic assessment of ACP-001 by AUC", 
                "measure": "Pharmacokinetics of ACP-001", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "IGF-I levels and change in IGF-I levels over a period of 26 weeks", 
                "measure": "IGF-I response", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Number of injection site reactions", 
                "measure": "Local tolerability  of ACP-001", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Incidence of anti-hGH antibodies", 
                "measure": "Safety of ACP-001 on different dosing levels", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947907"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Height velocity over a period of 26 weeks (annualized)", 
            "measure": "Height velocity", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "source": "Ascendis Pharma A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ascendis Pharma A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}